Francis J Giles

Francis J Giles

UNVERIFIED PROFILE

Are you Francis J Giles?   Register this Author

Register author
Francis J Giles

Francis J Giles

Publications by authors named "Francis J Giles"

Are you Francis J Giles?   Register this Author

100Publications

2936Reads

25Profile Views

The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.

EMBO Mol Med 2019 Sep 26:e10659. Epub 2019 Sep 26.

Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15252/emmm.201910659DOI Listing
September 2019

Nivolumab in metastatic adrenocortical carcinoma: results of a phase II trial.

J Clin Endocrinol Metab 2019 Jul 5. Epub 2019 Jul 5.

Developmental Therapeutics Program, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2019-00600DOI Listing
July 2019

Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.

Oncologist 2019 Jun 13;24(6):820-828. Epub 2019 Mar 13.

Developmental Therapeutics Program of Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0433DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656496PMC
June 2019

Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses.

Cancer Biol Ther 2019 12;20(8):1047-1056. Epub 2019 Apr 12.

a Lifespan Cancer Institute, Division of Hematology/Oncology , The Warren Alpert Medical School of Brown University , Providence , RI , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2019.1595283DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606036PMC
April 2019

Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors.

Clin Cancer Res 2018 04 6;24(8):1785-1794. Epub 2017 Dec 6.

Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, California.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-17-1970DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899646PMC
April 2018

Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.

Oncologist 2018 04 14;23(4):410-421. Epub 2017 Dec 14.

Developmental Therapeutics Program of Division of Hematology Oncology, Northwestern University, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2017-0354DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896702PMC
April 2018

Role of artificial intelligence in the care of patients with nonsmall cell lung cancer.

Eur J Clin Invest 2018 Apr 19;48(4). Epub 2018 Feb 19.

Developmental Therapeutics Consortium, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/eci.12901DOI Listing
April 2018

Immune checkpoint pathways in non-small cell lung cancer.

Ann Transl Med 2018 Mar;6(5):88

Developmental Therapeutics Program of the Division of Hematology Oncology, Northwestern University, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2017.09.30DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890048PMC
March 2018

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.

Mol Cancer Ther 2017 Dec;16(12):2645-2655

Developmental Therapeutics Program, Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-0597DOI Listing
December 2017

Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib.

Breast 2017 Oct 12;35:1-7. Epub 2017 Jun 12.

Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2017.05.016DOI Listing
October 2017

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.

Oncotarget 2017 Oct 13;8(51):89284-89306. Epub 2017 Jun 13.

Developmental Therapeutics Program, Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/18467
Publisher Site
http://dx.doi.org/10.18632/oncotarget.18467DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687690PMC
October 2017

Overcoming immunosuppression in bone metastases.

Crit Rev Oncol Hematol 2017 Sep 12;117:114-127. Epub 2017 May 12.

Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2017.05.004DOI Listing
September 2017

Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review.

Oncotarget 2017 Aug 3;8(34):57889-57897. Epub 2017 Jun 3.

Developmental Therapeutics Program of the Division of Hematology Oncology, Northwestern University, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.18361DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593692PMC
August 2017

Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.

Mol Cancer Ther 2017 07 26;16(7):1412-1420. Epub 2017 Apr 26.

Developmental Therapeutics Program of Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-0061DOI Listing
July 2017

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.

Cancer Manag Res 2017 14;9:207-213. Epub 2017 Jun 14.

Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

View Article

Download full-text PDF

Source
https://www.dovepress.com/clinical-features-diagnostic-chall
Publisher Site
http://dx.doi.org/10.2147/CMAR.S136818DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476791PMC
June 2017

Developmental therapeutics for inflammatory breast cancer: Biology and translational directions.

Oncotarget 2017 Feb;8(7):12417-12432

Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.13778DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355355PMC
February 2017

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development.

Cancer Treat Rev 2017 Feb 5;53:111-119. Epub 2017 Jan 5.

Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, USA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.12.010DOI Listing
February 2017

Genomic characterization of high-risk non-muscle invasive bladder cancer.

Oncotarget 2016 Nov;7(46):75176-75184

Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.12661DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342732PMC
November 2016

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives.

Drug Des Devel Ther 2016 29;10:873-84. Epub 2016 Feb 29.

Northwestern Medicine Developmental Therapeutics Institute, Robert H Lurie Comprehensive Cancer Center of Northwestern University, IL, USA; Division of Hematology and Oncology, Feinberg School of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DDDT.S93459DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778792PMC
October 2016

Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?

Clin Lung Cancer 2016 09 6;17(5):350-361. Epub 2016 Apr 6.

Developmental Therapeutics Program of the Division of Hematology Oncology, Department of Medicine, Northwestern Medicine Developmental Therapeutics Institute, Northwestern University, Chicago, IL; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.03.011DOI Listing
September 2016

FGFR3-TACC3 fusion in solid tumors: mini review.

Oncotarget 2016 08;7(34):55924-55938

Developmental Therapeutics Program, Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.10482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342462PMC
August 2016

The challenge of developmental therapeutics for adrenocortical carcinoma.

Oncotarget 2016 Jul;7(29):46734-46749

Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.8774DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216833PMC
July 2016

Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo.

Blood 2016 07 15;128(3):410-4. Epub 2016 Jun 15.

Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL; and Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-02-698704DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957163PMC
July 2016

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Cancer Discov 2016 06 21;6(6):601-11. Epub 2016 Apr 21.

Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee. Addario Lung Cancer Medical Institute, Cambridge, Massachusetts. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-0075DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893907PMC
June 2016

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes.

Cell Cycle 2015 ;14(14):2219-21

a Center for Personalized Cancer Therapy; Division of Hematology and Oncology; UC San Diego Moores Cancer Center ; San Diego , CA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2015.1041695DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615125PMC
April 2016

Is Personalized Medicine Here?

Oncology (Williston Park) 2016 Apr;30(4):293-303, 307

View Article

Download full-text PDF

Source
April 2016

Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms.

EBioMedicine 2016 Jan 13;3:17-25. Epub 2016 Jan 13.

Robert H. Lurie Comprehensive Cancer Center and Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States; Northwestern Medicine Developmental Therapeutics Institute (NMDTI), Northwestern University, Chicago, IL, United States; Jesse Brown Veterans Affairs Medical Center, Chicago, IL, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2016.01.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739416PMC
January 2016

Blinatumomab for the treatment of acute lymphoblastic leukemia.

Invest New Drugs 2015 Dec 17;33(6):1271-9. Epub 2015 Sep 17.

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 233 E. Superior St., First floor, Chicago, IL, 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0289-4DOI Listing
December 2015

Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.

Clin Cancer Res 2015 Dec 30;21(24):5427-33. Epub 2015 Oct 30.

Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Northwestern Brain Tumor Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0420DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681601PMC
December 2015

Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling.

Oncotarget 2015 Nov;6(35):37117-34

Northwestern Medicine Developmental Therapeutics Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.5076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741919PMC
November 2015

Human endogenous retrovirus K and cancer: Innocent bystander or tumorigenic accomplice?

Int J Cancer 2015 Sep 17;137(6):1249-57. Epub 2014 Jun 17.

Prostate Cancer Institute, National University of Ireland Galway, Galway, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.29003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264888PMC
September 2015

Targeted therapies in advanced differentiated thyroid cancer.

Cancer Treat Rev 2015 Sep 17;41(8):690-8. Epub 2015 Jun 17.

Northwestern Medicine Developmental Therapeutics Institute, Northwestern University, United States; Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, United States; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2015.06.002DOI Listing
September 2015

Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.

Expert Rev Hematol 2015 Aug 4;8(4):457-79. Epub 2015 May 4.

Northwestern Medicine Developmental Therapeutics Institute, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2015.1041910DOI Listing
August 2015

FGFR3-TACC3: A novel gene fusion in cervical cancer.

Gynecol Oncol Rep 2015 Aug 18;13:53-6. Epub 2015 Jun 18.

Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University 645 N Michigan Ave Suite 1006 Chicago, IL, 60611, Unites States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gore.2015.06.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563584PMC
August 2015

Predicting resistance to dasatinib therapy for patients with Philadelphia-positive leukemia with prior tyrosine kinase inhibitor failure.

Leuk Lymphoma 2015 Jul 21;56(7):1922-3. Epub 2015 Jan 21.

Northwestern Medicine Developmental Therapeutics Institute, Northwestern University , Chicago, IL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.999332DOI Listing
July 2015

Synthetic high-density lipoprotein-like nanoparticles as cancer therapy.

Cancer Treat Res 2015 ;166:129-50

Feinberg School of Medicine, Department of Urology, Northwestern University, Tarry 16-703, 303 E. Chicago Ave, Chicago, IL, 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-16555-4_6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418545PMC
July 2015

Targeted therapy of acute myeloid leukemia.

Expert Rev Anticancer Ther 2015 Apr 26;15(4):399-413. Epub 2015 Jan 26.

Northwestern Developmental Therapeutics Institute, Northwestern University Feinberg School of Medicine, 645 N Michigan Ave. Suite 1006, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.2015.1004316DOI Listing
April 2015

Emerging therapeutic targets in bladder cancer.

Cancer Treat Rev 2015 Feb 24;41(2):170-8. Epub 2014 Nov 24.

Northwestern Medicine Developmental Therapeutics Institute, Feinberg School of Medicine, Northwestern University, United States; Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, United States; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2014.11.003DOI Listing
February 2015

Synthetic high-density lipoprotein-like nanoparticles for cancer therapy.

Expert Rev Anticancer Ther 2015 Jan 9;15(1):27-34. Epub 2014 Dec 9.

Department of Urology, Feinberg School of Medicine, Northwestern University, Tarry 16-703, 303 E. Chicago Ave. Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.2015.990889DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4638421PMC
January 2015

NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.

Mol Cancer Ther 2014 Dec 13;13(12):2919-29. Epub 2014 Oct 13.

Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Northwestern Medicine Developmental Therapeutics Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-14-0306DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364529PMC
December 2014

The role of inflammation in leukaemia.

Adv Exp Med Biol 2014 ;816:335-60

Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2F978-3-0348-08
Web Search
http://link.springer.com/10.1007/978-3-0348-0837-8_13
Publisher Site
http://dx.doi.org/10.1007/978-3-0348-0837-8_13DOI Listing
September 2014

Targeted therapies for cutaneous T-cell lymphomas.

Expert Rev Hematol 2014 Aug;7(4):481-93

Northwestern Medicine Developmental Therapeutics Institute, Northwestern University, 645 N. Michigan Ave, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2014.942279DOI Listing
August 2014

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.

J Clin Oncol 2014 Jun 19;32(18):1919-26. Epub 2014 May 19.

Gail J. Roboz, Weill Cornell Medical College and the New York Presbyterian Hospital; Todd Rosenblat, Columbia University Medical Center, New York, NY; Martha Arellano, Winship Cancer Institute at Emory University; Scott R. Solomon, The Blood and Marrow Transplant Group of Georgia, Atlanta, GA; Jessica K. Altman, Francis J. Giles, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Casey O'Connell, University of Southern California Norris Comprehensive Cancer Center and Hospital, Los Angeles, CA; Marco Gobbi, Azienda Ospedaliera Universitaria San Martino, University of Genoa, Genoa, Italy; Pau Montesinos, Hospital Universitario y Politécnico La Fé, Valencia, Spain; Arnaud Pigneux, Centre Hospitalier Universitaire de Bordeaux Hôpital Haut-Lévêque, Pessac; Norbert Vey, L'Institut Paoli-Calmettes, Marseilles, France; Robert Hills, Cardiff University School of Medicine, Cardiff, United Kingdom; Tove Flem Jacobsen, Athos Gianella-Borradori, Øivind Foss, and Sylvia Vetrhus, Clavis Pharma ASA, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.8562DOI Listing
June 2014

Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting.

Clin Cancer Res 2014 May 7;20(9):2400-9. Epub 2014 Mar 7.

Authors' Affiliations: Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Division of Hematology/Oncology, Department of Medicine; Department of Radiology, Northwestern University, Feinberg School of Medicine; and Division of Hematology-Oncology, Department of Medicine, Jesse Brown VA Medical Center, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-3218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056773PMC
May 2014

Use of mTOR inhibitors in the treatment of malignancies.

Expert Opin Pharmacother 2014 May 25;15(7):979-90. Epub 2014 Mar 25.

Northwestern University , Chicago, IL , USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2014.899582DOI Listing
May 2014

New strategies for relapsed acute myeloid leukemia: fertile ground for translational research.

Curr Opin Hematol 2014 Mar;21(2):79-86

Division of Hematology/Oncology and Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University-Feinberg School of Medicine, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOH.0000000000000018DOI Listing
March 2014

Inhibition of protein synthesis and JNK activation are not required for cell death induced by anisomycin and anisomycin analogues.

Biochem Biophys Res Commun 2014 Jan 12;443(2):761-7. Epub 2013 Dec 12.

Pharmacology and Therapeutics, National Centre for Biomedical Engineering Research, National University of Ireland Galway, Galway, Ireland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2013.12.041DOI Listing
January 2014

Perifosine--a new option in treatment of acute myeloid leukemia?

Expert Opin Investig Drugs 2013 Oct 9;22(10):1315-27. Epub 2013 Aug 9.

Galway University Hospital , Newcastle Rd, Galway , Ireland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2013.826648DOI Listing
October 2013

Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.

Clin Cancer Res 2013 Jul 15;19(14):3996-4007. Epub 2013 Apr 15.

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-2079DOI Listing
July 2013

5-Azacytidine for the treatment of myelodysplastic syndromes.

Expert Opin Pharmacother 2013 Jun 27;14(9):1255-68. Epub 2013 Apr 27.

Galway University Hospital, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2013.794222DOI Listing
June 2013

Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.

Eur J Clin Pharmacol 2013 Apr 5;69(4):813-23. Epub 2012 Oct 5.

HRB Clinical Research Facility, Galway, and Trinity College, National University of Ireland, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00228-012-1385-4DOI Listing
April 2013

The yin and yang of nitric oxide in cancer progression.

Carcinogenesis 2013 Mar 25;34(3):503-12. Epub 2013 Jan 25.

Prostate Cancer Institute, National University of Ireland Galway, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgt034DOI Listing
March 2013

Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.

Expert Rev Hematol 2013 Feb;6(1):9-24

HRB Clinical Research Facility, National University of Ireland Galway, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.12.68DOI Listing
February 2013

Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.

Int J Cancer 2012 Dec 28;131(11):2693-703. Epub 2012 Jun 28.

Division of Hematology and Medical Oncology, Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.27579DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419336PMC
December 2012

An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma.

Biochem Biophys Res Commun 2012 Sep 30;426(3):363-8. Epub 2012 Aug 30.

Pediatric Cancer Biology Program, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2012.08.092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463776PMC
September 2012

Clinical cardiac safety profile of nilotinib.

Haematologica 2012 Jun 22;97(6):883-9. Epub 2012 Jan 22.

Medizinische Klinik mS Hämatologie und Onkologie, Charité -Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2011.058776DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366654PMC
June 2012

EPHA3 as a novel therapeutic target in the hematological malignancies.

Expert Rev Hematol 2012 Jun;5(3):325-40

HRB Clinical Research Facility, National University of Ireland Galway, University Road, Galway, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.12.19DOI Listing
June 2012

Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model.

J Pediatr Hematol Oncol 2012 Mar;34(2):116-21

Greehey Children's Cancer Research Institute, University of Texas Health Science Center, San Antonio, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0b013e3182309fe4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250428PMC
March 2012

Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?

Expert Rev Hematol 2012 Feb;5(1):17-26

Mayo Clinic Phoenix Campus, Department of Hematology & Oncology, 5777 East Mayo Boulevard, Phoenix, AZ 85054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.11.68DOI Listing
February 2012

The PIM kinases in hematological cancers.

Expert Rev Hematol 2012 Feb;5(1):81-96

Department of Hematology/Oncology, Cancer Therapy & Research Center, The University of Texas Health Science Center San Antonio, 7979 Wurzbach Road, MC8232, San Antonio, 78229, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.11.69DOI Listing
February 2012